NewAmsterdam Pharma Co N.V.
Business
NewAmsterdam Pharma Co N.V. is a late-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for cardiometabolic diseases, primarily to lower LDL cholesterol in patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia. The company is investigating obicetrapib as both a monotherapy and as a fixed-dose combination with ezetimibe through multiple Phase 3 clinical trials, including the cardiovascular outcomes trial PREVAIL. NewAmsterdam has partnered with Menarini for commercialization rights in majority European territories and is pursuing development and commercialization in the United States and other jurisdictions.
Summary from 10-K filed 2026-02-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 23 | 46 | 14 | 103 | — | |
| Research and development expenses | 142 | 151 | 159 | 87 | 29 | |
| Selling, general and administrative expenses | 106 | 70 | 38 | 20 | 6 | |
| Total operating expenses | 248 | 222 | 197 | 106 | 35 | |
| Operating loss | −226 | −176 | −183 | −4 | −35 | |
| Interest income | 28 | 17 | 11 | — | — | |
| Fair value change - earnout | 4 | −37 | −266,000 | −707,000 | — | |
| Fair value change - warrants | −23 | −39 | −10 | −334,000 | — | |
| Foreign exchange gains/(losses) | 13 | −7 | 5 | −10 | 2 | |
| Loss before tax | −204 | −242 | −177 | −23 | −42 | |
| Income tax expense (benefit) | — | −1,000 | 27,000 | — | — | |
| Loss for the year | −204 | −242 | −177 | −23 | −42 | |
| Unrealized gain on available-for-sale securities, net of tax | 326,000 | 45,000 | — | — | — | |
| Total comprehensive loss for the year, net of tax | −203 | −242 | −177 | −12 | −41 | |
| Basic | −1.72 | −2.56 | −2.15 | −1.19 | −3.81 | |
| Diluted | −1.72 | −2.56 | −2.15 | −1.19 | −3.81 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 490 | 772 | 340 | — | — | |
| Prepayments and other receivables | 38 | 24 | 6 | 10 | — | |
| Employee receivables | — | 5 | — | — | — | |
| Marketable securities, current | 146 | 62 | — | — | — | |
| Restricted cash | 1 | — | — | — | — | |
| Total current assets | 676 | 863 | 347 | 478 | — | |
| Marketable securities, net of current portion | 93 | — | — | — | — | |
| Property, plant and equipment, net | 383,000 | 242,000 | 46,000 | 34,000 | — | |
| Operating right of use asset | 185,000 | 431,000 | 55,000 | 120,000 | — | |
| Intangible assets | 407,000 | 534,000 | 170,000 | 208,000 | — | |
| Total assets | 769 | 865 | 347 | 478 | — | |
| Accounts payable | 9 | 5 | 17 | 12 | — | |
| Accrued expenses and other current liabilities | 15 | 14 | 11 | 6 | — | |
| Deferred revenue, current | 4 | 6 | 9 | 14 | — | |
| Lease liability, current | 136,000 | 246,000 | 60,000 | 66,000 | — | |
| Derivative earnout liability, current | — | 45 | — | — | — | |
| Derivative warrant liabilities | 57 | 38 | 13 | 4 | — | |
| Total current liabilities | 86 | 107 | 50 | 36 | — | |
| Lease liability, net of current portion | 66,000 | 202,000 | — | 60,000 | — | |
| Total liabilities | 86 | 107 | 59 | 48 | — | |
| Commitments and contingencies (Note 13) | — | — | — | — | — | |
| Ordinary shares | 14 | 13 | 10 | 10 | — | |
| Additional paid-in capital | 1,427 | 1,298 | 591 | 556 | — | |
| Accumulated loss | −762 | −559 | −317 | −140 | — | |
| Accumulated other comprehensive income | 5 | 4 | 4 | 4 | — | |
| Total shareholders' equity | 683 | 758 | 288 | 430 | −114 | |
| Total liabilities and shareholders' equity | 769 | 865 | 347 | 478 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Loss for the year | −204 | −242 | −177 | −23 | −42 | |
| Depreciation and amortization | 220,000 | 113,000 | 49,000 | 9,000 | 5,000 | |
| Non-cash rent expense | — | 12,000 | 6,000 | 10,000 | 2,000 | |
| Fair value change - derivative earnout and warrants | 19 | 76 | 10 | 1 | — | |
| Loss on disposal of property, plant and equipment | 12,000 | — | — | — | — | |
| Amortization of premium/discount on available-for-sale debt securities | −1 | −227,000 | — | — | — | |
| Share-based compensation | 59 | 34 | 25 | 4 | 1 | |
| Changes in prepayments (current and non-current) and other receivables | −13 | −17 | 4 | −4 | −5 | |
| Changes in accounts payable | 5 | −13 | 5 | 5 | 7 | |
| Changes in accrued expenses and other current liabilities | 2 | 2 | 5 | −9 | 3 | |
| Changes in deferred revenue | −2 | −4 | −9 | 18 | — | |
| Net cash used in operating activities | −148 | −159 | −141 | 11 | −30 | |
| Purchase of property, plant and equipment, including internal use software | −246,000 | −672,000 | −24,000 | −221,000 | −24,000 | |
| Maturities of marketable securities | 122 | — | — | — | — | |
| Purchases of marketable securities | −297 | −62 | — | — | — | |
| Net cash used in investing activities | −175 | −63 | −24,000 | −221,000 | −24,000 | |
| Proceeds from exercise of warrants | 2 | 14 | 9 | — | — | |
| Proceeds from exercise of options | 29 | 2 | 290,000 | — | — | |
| Payment of withholding taxes related to net share settlement of exercised options | — | −989,000 | — | — | — | |
| Net cash provided by financing activities | 30 | 660 | 9 | 392 | 85 | |
| Net change in cash, cash equivalents and restricted cash | −293 | 438 | −132 | 402 | 55 | |
| Foreign exchange differences | 13 | −7 | 5 | 5 | −5 | |
| Recognition of ROU asset | — | 562,000 | — | — | 196,000 | |
| Issuance of earnout shares | 41 | — | — | — | — | |
| Cash paid for income taxes | — | 1,000 | 27,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is NewAmsterdam Pharma Co N.V.'s CIK number?
NewAmsterdam Pharma Co N.V.'s SEC CIK number is 0001936258 (1936258). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find NewAmsterdam Pharma Co N.V.'s SEC filings?
All of NewAmsterdam Pharma Co N.V.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did NewAmsterdam Pharma Co N.V. last report earnings?
NewAmsterdam Pharma Co N.V. (NAMS) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-210283). This is NewAmsterdam Pharma Co N.V.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is NewAmsterdam Pharma Co N.V.'s most recent earnings 8-K?
NewAmsterdam Pharma Co N.V.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-210283. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View NewAmsterdam Pharma Co N.V.'s latest earnings 8-K →
Look up any company's CIK number →